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n Abstract: Benign breast disease (BBD) is a very common condition, diagnosed in approximately half of all American
women throughout their lifecourse. White women with BBD are known to be at substantially increased risk of subsequent
breast cancer; however, nothing is known about breast cancer characteristics that develop after a BBD diagnosis in Afri-
can-American women. Here, we compared 109 breast cancers that developed in a population of African-American women
with a history of BBD to 10,601 breast cancers that developed in a general population of African-American women whose
cancers were recorded by the Metropolitan Detroit Cancer Surveillance System (MDCSS population). Demographic and
clinical characteristics of the BBD population were compared to the MDCSS population, using chi-squared tests, Fisher’s
exact tests, t-tests, and Wilcoxon tests where appropriate. Kaplan–Meier curves and Cox regression models were used to
examine survival. Women in the BBD population were diagnosed with lower grade (p = 0.02), earlier stage cancers
(p = 0.003) that were more likely to be hormone receptor-positive (p = 0.03) compared to the general metropolitan Detroit
African-American population. In situ cancers were more common among women in the BBD cohort (36.7%) compared to
the MDCSS population (22.1%, p < 0.001). Overall, women in the BBD population were less likely to die from breast cancer
after 10 years of follow-up (p = 0.05), but this association was not seen when analyses were limited to invasive breast can-
cers. These results suggest that breast cancers occurring after a BBD diagnosis may have more favorable clinical parame-
ters, but the majority of cancers are still invasive, with survival rates similar to the general African-American population. n
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Benign breast disease (BBD) is a very common con-dition, diagnosed in approximately half of all
American women at some point in their lives (1).
Along with age, reproductive factors and family his-
tory, it is well established that BBD raises long-term
breast cancer risk (2–7). Different types of BBD have
been associated with differentially elevated risk: non-
proliferative lesions confer a relatively low level of
additional risk, while proliferative lesions with atypia
confer a much greater risk (7,8). However, although
lesions differentially elevate breast cancer risk, little is
known about whether different lesions predict the
development of specific types of breast cancer (9).
There are known racial disparities between African-
American and white women in the epidemiology of
breast cancer. For example, African-American women
develop breast cancer at a younger age and present
with more advanced tumors (10–12). Despite these
differences, recent research has suggested that the
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association between BBD and breast cancer first described
in white women also applies to African-American women
(8,13). BBD and breast cancer may even be more
strongly associated in African-American women than
they are in white women (14). Therefore, it is impor-
tant to better characterize the association between
BBD and breast cancer in African-American women.
Although it is well known that BBD elevates risk of
breast cancer, no studies have compared the breast
cancer characteristics of women with a history of BBD
to the breast cancer characteristics of the general popu-
lation. Such a comparison is of interest because women
with BBD are at elevated risk for breast cancer, so it is
important to determine whether their tumors are clini-
cally different from those of the general population. It
is possible that because women who have been diag-
nosed with BBD have established access to medical
care and some awareness of breast health, their cancers
will be diagnosed earlier. In this study, we will com-
pare the characteristics of breast cancers in women
with a history of BBD to the characteristics of breast
cancers in a large population-based sample of women.
MATERIALS AND METHODS
Populations Studied
The BBD cohort was composed of women who self-
reported African-American/black race from metropoli-
tan Detroit, MI, who had been diagnosed with BBD
between 1997 and 2003 at hospitals and clinics associ-
ated with the Detroit Medical Center. The BBD cohort
was previously described by Cote et al. (13). In brief,
exclusion criteria included: a previous breast biopsy, a
history of invasive or in situ breast carcinoma prior to,
or within 6 months, of the BBD biopsy, unilateral or
bilateral mastectomy prior to or at diagnosis, prior
breast reduction surgery, lipoma, fat necrosis, epider-
mal cysts, hematoma, accessory structure, phyllodes
tumor, or a lymph node biopsy with no breast tissue.
Women from the BBD cohort who subsequently devel-
oped breast cancer before the second quarter of 2013
comprised the BBD population.
The referent population was selected from the
Metropolitan Detroit Cancer Surveillance System
(MDCSS) data base, a founding member of the Sur-
veillance, Epidemiology, and End Results (SEER) pro-
gram. The MDCSS population was composed of
African-American women who were diagnosed with
breast cancer between 1998 and 2012 and who lived
in the tri-county Metropolitan Detroit area. The SEER
program collected estrogen receptor (ER) and proges-
terone receptor (PR) status during this time period,
but HER2 status was not a required variable until
2010 and thus is not included in this analysis for
either population. To ensure comparability between
the BBD population and the MDCSS population, girls
under the age of 18 and women diagnosed with
inflammatory breast cancer or Paget’s Disease were
excluded from analysis. In addition, to ensure that
analyses reflected the experiences of women with
breast cancer, women who died less than 2 months
after breast cancer diagnosis were excluded from both
populations. Data were accessed on June 12, 2013.
Statistical Analysis
Demographic and clinical characteristics of the BBD
population were compared to the MDCSS population,
using chi-squared tests, Fisher’s exact tests, t-tests, and
Wilcoxon tests where appropriate. Known predictors
of survival (age, hormone receptor status, tumor grade,
tumor stage, in situ or invasive behavior, tumor size,
and treatment variables) were evaluated. Age was eval-
uated in 10-year intervals (<40 years, 40–49 years,
50–59 years, 60–69 years, ≥70 years) in descriptive
statistics, and as a continuous variable in the Cox
regression models. Hormone receptor status was
divided into two categories: ER or PR positive versus
both ER and PR negative, in accordance with clinically
significant differences in hormone receptor status (15).
Tumor grade was recorded from the MDCSS and
coded as I, II, or III/IV. Tumor stage was recorded
from the MDCSS and categorized as in situ, localized,
regional, or distant. Tumor size was categorized in
accordance with American Joint Committee on Cancer
(AJCC) guidelines (≤20 mm, >20–50 mm, >50 mm)
(16). Radiation and surgery were both evaluated as
dichotomous variables. Other characteristics, namely
marital status and number of previous cancers, were
also evaluated. Characteristics were examined overall
and stratified by in situ or invasive status. Variables in
which more than 15% of observations were unknown
were evaluated both with and without the unknown
category in descriptive statistics, and with the
unknown category in the Cox regression models.
Kaplan–Meier curves were used to evaluate overall
and breast cancer-specific survival over a 10-year
follow-up, in all women and in women with invasive
breast cancer only. Hazard ratios for overall survival
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and breast cancer-specific survival were estimated
using Cox regression models adjusted for age, marital
status, number of previous cancers, hormone receptor
status (ER/PR, ER+ and/or PR+, or Unknown),
tumor grade (I, II, or III/IV), stage (in situ, localized,
regional, or distant), size (divided according to AJCC
staging guidelines), radiation, and surgery. SAS 9.2
(Cary, NC) was used for all analyses.
RESULTS
Population Characteristics
The BBD population consisted of 109 women with
a history of BBD, who were diagnosed with breast
cancer before the second quarter of 2013. BBD popu-
lation women were aged 29–85 years (median
age = 59.0 years) at time of cancer diagnosis (median
survival among deceased = 2.9 years). The MDCSS
population was composed of 10,601 African-Ameri-
can women within the MDCSS catchment area.
MDCSS women were aged 18–107 years (median
age = 58.0 years) at time of cancer diagnosis (median
survival among deceased = 2.9 years). Women in the
BBD population did not differ from the MDCSS popu-
lation in age, marital status at breast cancer diagnosis,
number of previous cancers, length of survival after
diagnosis among deceased, or in breast cancer treat-
ment (surgery or radiation; Table 1).
Tumor Characteristics
Women in the BBD population did not differ from
the MDCSS population with respect to tumor size, but
were significantly more likely to develop breast cancers
that were hormone receptor-positive (excluding unkn-
own group, 81.7% versus 69.6%, p = 0.027), in situ
rather than invasive (36.7% versus 22.1%, p < 0.001),
early stage (37.7% versus 22.6%, p = 0.003), and low
grade (25.0% versus 14.5%, p = 0.020), when com-
pared to the MDCSS population (Table 1).
In stratified analysis examining invasive cancers
only, the BBD population remained more likely to be
diagnosed with hormone receptor-positive tumors
(excluding unknown group, 78.0% versus 66.5%,
p = 0.062) and more likely to be alive at last follow-
up (75.4% versus 63.6%, p = 0.044), although the
length of survival after diagnosis among deceased indi-
viduals did not differ between populations. Among in
situ cancers only, BBD women were more likely to be
diagnosed with low-grade tumors (45.2% versus
24.0%, p = 0.021; Table 2).
Survival
Compared to the MDCSS population, BBD popula-
tion women had a moderately lower risk of death
Table 1. Demographic and Clinical Characteristics







(n = 109) p-value
Percentage of total 99.0% 1.0%
Age at diagnosis
<40 years 639 (6.0) 4 (3.7) 0.321
40–49 years 2083 (19.7) 16 (14.7)
50–59 years 2887 (27.2) 38 (34.9)
60–69 years 2289 (21.6) 24 (22.0)
≥70 years 2703 (25.5) 27 (24.8)
Median age (years) 58.0  0.1 59.0  1.2 0.724
Marital status at diagnosis1
Single 3020 (30.0) 34 (32.4) 0.873
Married 3477 (34.6) 35 (33.3)
Other 3556 (35.4) 36 (34.3)
No. of previous cancers
0 8115 (76.6) 85 (78.0) 0.408
1 1214 (11.4) 15 (13.8)
≥2 1272 (12.0) 9 (8.3)
Vital status as of 2012
Alive 7241 (68.3) 87 (79.8) 0.010*
Deceased 3360 (31.7) 22 (20.2)
Survival (years)
among deceased2
2.9  0.1 2.9  0.5 0.406
Hormone receptor status
ER+ or PR+ 5677 (53.5) 58 (53.2) 0.002*/0.027*8
ER/PR 2479 (23.4) 13 (11.9)
Unknown 2445 (23.1) 38 (34.9)
Tumor grade3
I 1340 (14.5) 22 (25.0) 0.020*
II 3240 (35.1) 29 (33.0)
III/IV 4648 (50.4) 37 (42.0)
Tumor stage4
In situ 2347 (22.6) 40 (37.7) 0.003*
Localized 4382 (42.2) 36 (34.0)
Regional 2994 (28.8) 25 (23.6)
Distant 668 (6.4) 5 (4.7)
Tumor behavior
In situ 2347 (22.1) 40 (36.7) <0.001*
Invasive 8254 (77.9) 69 (63.3)
Tumor size5
≤20 mm 4929 (53.8) 47 (50.5) 0.816
>20–50 mm 3194 (34.9) 35 (37.6)
>50 mm 1037 (11.3) 11 (11.8)
Radiation6
Yes 5137 (50.0) 61 (57.0) 0.152
No 5127 (50.0) 46 (43.0)
Surgery7
Yes 9548 (90.3) 99 (90.8) 0.867
No 1020 (9.7) 10 (9.2)
Percentages may not sum to 100% due to rounding. Plus-minus values are medi-
ans  SE.
Missing observations among all women: 1548; 237; 31373; 4210; 51441; 6337; 733.
Missing observations among biopsied women: 14; 3c21; 43; 516; 62.
8The first p-value indicates the chi-squared probability including the “Unknown” group.
The second p-value indicates the chi-squared probability excluding the “Unknown” group.
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from any cause (p = 0.084) and a lower risk of death
from breast cancer specifically (p = 0.047) over
10 years of follow-up after diagnosis. However, when
analyzing invasive cancers only, the BBD and MDCSS
populations did not differ in risk of death from any
cause or from breast cancer (Fig. 1).
In both the MDCSS population and the BBD
population, risk of death from any cause was signifi-
cantly associated with known predictors of survival:
increasing age at breast cancer diagnosis, hormone
receptor-negativity, increasing grade, increasing stage,
increasing tumor size, not receiving radiation or
surgery, and at least one previous cancer diagnosis
(Table 3). All of these factors, with the exception
of having had a previous cancer diagnosis, also
significantly elevated risk of breast cancer-specific
death in the adjusted models (Table 3). Membership
in the BBD population was not significantly associ-
ated with risk of death in the adjusted models
(Table 3).
Table 2. Demographic and Clinical Characteristics of Cancers in MDCSS and BBD Women, Stratified
by Invasive Versus In Situ Disease
Characteristic
Invasive cancer In situ cancer
MDCSS population BBD population p-value MDCSS population BBD population p-value
Age at diagnosis
<40 years 569 (6.9) 3 (4.3) 0.378 70 (3.0) 1 (2.5) 0.510
40–49 years 1624 (19.7) 8 (11.6) 459 (19.6) 8 (20.0)
50–59 years 2173 (26.3) 21 (30.4) 714 (30.4) 17 (42.5)
60–69 years 1746 (21.2) 18 (26.1) 543 (23.1) 6 (15.0)
≥70 years 2142 (26.0) 19 (27.5) 561 (23.9) 8 (20.0)
Median age (years) 58.0  0.2 61.0  1.5 0.297 59.0  0.3 56.0  1.8 0.334
Marital status at diagnosis1
Single 2380 (30.4) 20 (30.3) 0.680 640 (28.7) 14 (35.9) 0.428
Married 2600 (33.3) 19 (28.8) 877 (39.3) 16 (41.0)
Other 2840 (36.3) 27 (40.9) 716 (32.1) 9 (23.1)
No. of previous cancers
0 6406 (77.6) 54 (78.3) 0.907 1709 (72.8) 31 (77.5) 0.298
1 883 (10.7) 8 (11.6) 331 (14.1) 7 (17.5)
≥2 965 (11.7) 7 (10.1) 307 (13.1) 2 (5.0)
Vital status as of 2012
Alive 5254 (63.6) 52 (75.4) 0.044* 1987 (84.7) 35 (87.5) 0.621
Deceased 3000 (36.4) 17 (24.6) 360 (15.3) 5 (12.5)
Survival (years) among
deceased2
2.7  0.1 2.3  0.5 0.605 5.2  0.2 5.7  1.3 0.783
Hormone receptor status
ER+ or PR+ 4685 (56.8) 46 (66.7) 0.176/0.062*8 992 (42.3) 12 (30.0) 0.062/0.6258
ER/PR 2363 (28.6) 13 (18.8) 116 (4.9) 0 (0)
Unknown 1206 (14.6) 10 (14.5) 1239 (52.8) 28 (70.0)
Tumor grade3
I 901 (12.2) 8 (14.0) 0.730 439 (24.0) 14 (45.2) 0.021*
II 2478 (33.5) 21 (36.8) 762 (41.6) 8 (25.8)
III/IV 4019 (54.3) 28 (49.1) 629 (34.4) 9 (29.0)
Tumor stage4
In situ – – 0.976 2347 (100.0) 40 (100.0) –
Localized 4382 (54.5) 36 (54.6) – –
Regional 2994 (37.2) 25 (37.9) – –
Distant 668 (8.3) 5 (7.6) – –
Tumor size5
≤20 mm 3700 (49.0) 25 (39.1) 0.280 1229 (76.4) 22 (75.9) 0.987
>20–50 mm 2941 (38.6) 30 (46.9) 280 (17.4) 5 (17.2)
>50 mm 938 (12.4) 9 (14.1) 99 (6.2) 2 (6.9)
Radiation6
Yes 4100 (51.5) 43 (64.2) 0.039* 1037 (45.0) 18 (45.0) 0.997
No 3861 (48.5) 24 (35.8) 1266 (55.0) 22 (55.0)
Surgery7
Yes 7316 (89.0) 62 (89.9) 0.819 2232 (95.1) 37 (92.5) 0.446
No 905 (11.0) 7 (10.1) 115 (4.9) 3 (7.5)
Percentages may not sum to 100% due to rounding. Plus-minus values are medians  SE. Missing observations among in situ cancers: MDCSS women: 1114; 21; 3517; 5739; 644. BBD
women: 11; 39; 511. Missing observations among invasive cancers: MDCSS women: 1434; 236; 3856; 4210; 5702; 6293; 733. BBD women: 13; 312; 43; 55; 62.
8The first p-value indicates the chi-squared probability including the “Unknown” group. The second p-value indicates the chi-squared probability excluding the “Unknown” group.
*indicates statistical significance.
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DISCUSSION
This is the first known study to compare the clini-
cal characteristics of breast cancers in women with a
history of BBD to those in the general population. In
addition, this study was done in a population of Afri-
can-American women, which adds a new perspective
to the literature on BBD and breast cancer that has
largely been done in white populations.
The cancers diagnosed in the BBD population were
much more likely to be in situ than were the cancers
diagnosed in the MDCSS population. In addition,
many of the differences between BBD population can-
cers and MDCSS population cancers appear to be due
to this difference in tumor behavior. For example, the
breast cancers developed by BBD women differed in
hormone receptor status, grade, stage, and in situ ver-
sus invasive disease from the breast cancers developed
by the MDCSS population, but the differences between
the BBD population and the MDCSS population disap-
peared almost entirely after controlling for in situ ver-
sus invasive disease. Similarly, BBD population women
were significantly less likely than MDCSS population
women to die from breast cancer over 10 years of fol-
low-up in overall survival analysis, but the survival differ-
ences between the populations were greatly reduced after
excluding women with in situ cancers from analysis.
Interestingly, women in the BBD population were
more likely than women in the MDCSS population to
develop hormone receptor-positive breast cancer
tumors, although results were somewhat limited by
the large proportion of tumors without records of hor-
mone receptor status. We included the unknown
group in the final analyses to maintain sufficient
power for the models. Previous studies that have
attempted to correlate tumor hormone receptor status
with history of BBD have reported null results (17) or
had insufficient data to draw a clear conclusion (18).
However, some research indicates that estradiol is ele-
vated in BBD tissue (19), and the ER-alpha gene is more
highly expressed in some types of BBD tissue (20), per-
haps favoring the later development of ER+ tumors in
women with BBD. Information regarding hormone
therapy use was not available for either cohort.
(a) (b)
(c) (d)
Figure 1. Survival curves comparing observed survival time of women in the BBD population (dashed line) and women in the MDCSS pop-
ulation (solid line). (a) Ten-year survival curves comparing observed survival time of all BBD population women and all MDCSS population
women. (b) Ten-year survival curves comparing observed breast cancer-specific survival time of BBD population women and MDCSS popu-
lation women. (c) Ten-year survival curves comparing observed survival time of women with invasive breast cancer from the BBD and the
MDCSS populations. (d) Ten-year survival curves comparing observed breast cancer-specific survival time of women with invasive breast
cancer from the BBD and the MDCSS populations.
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The breast cancer literature has not reached a con-
sensus as to whether in situ breast tumors represent a
stage in the multi-stage carcinogenesis pathway leading
to invasive breast cancers, or instead represent a risk
marker indicating elevated risk in all breast tissue (21).
This uncertainty allows several possible explanations
for our results. The difference may indicate that
women who receive medical attention for BBD are
more likely to have an established relationship with
the health care system, and therefore are screened
more frequently and are likely more aware of their
own breast health. These factors could lead to earlier
tumor detection of in situ cancers that would eventu-
ally have become invasive. This explanation is sup-
ported by the better 10-year breast cancer-specific
survival among BBD women reported in this study.
Alternatively, the difference may indicate that women
who have received a BBD diagnosis are more likely to
be subsequently over-screened, resulting in detection of
more subclinical in situ cancers that would not have
progressed, while not conferring a survival benefit to
women with invasive cancers. This explanation may be
supported by the greater proportion of in situ cancers
found in BBD population women, and the identical
median survival after diagnosis among the deceased
from both populations reported in this study.
This study had several limitations. First, the SEER
registry does not collect information on BBD in women
who develop breast cancer. We were therefore unable
to distinguish which women in the MDCSS population
may have been previously diagnosed with BBD. This
misclassification would bias results toward the null. In
addition, the SEER registry does not collect detailed
information about chemotherapy treatment, limiting




H.R. (95% CI) p-value
Breast cancer survival
H.R. (95% CI) p-value
Population
MDCSS Ref. – Ref. –
BBD 1.10 (0.67, 1.80) 0.71 0.97 (0.46, 2.05) 0.946
Age at diagnosis 1.03 (1.03, 1.03) <0.001* 1.01 (1.00, 1.01) <0.001*
Marital status at diagnosis
Single Ref. – Ref. –
Married 0.86 (0.77, 0.96) 0.007* 0.88 (0.76, 1.02) 0.072
Other 1.01 (0.90, 1.13) 0.874 1.02 (0.88, 1.18) 0.814
No. of previous cancers
0 Ref. – Ref. –
1 1.19 (1.05, 1.34) 0.006* 0.88 (0.73, 1.06) 0.190
≥2 1.34 (1.19, 1.52) <0.001* 1.17 (0.97, 1.41) 0.097
Hormone receptor status
ER+ or PR+ Ref. Ref. –
ER/PR 1.46 (1.37, 1.64) <0.001* 1.74 (1.53, 1.98) <0.001*
Unknown 1.26 (1.11, 1.42) <0.001* 1.39 (1.15, 1.68) <0.001*
Tumor grade
I Ref. – Ref. –
II 1.25 (1.06, 1.47) 0.008* 2.24 (1.57, 3.21) <0.001*
III/IV 1.62 (1.38, 1.91) <0.001* 3.23 (2.27, 4.59) <0.001*
Tumor stage
In situ Ref. – Ref. –
Localized 1.64 (1.37, 1.95) <0.001* 3.70 (2.43, 5.62) <0.001*
Regional 2.81 (2.35, 3.36) <0.001* 9.34 (6.18, 14.13) <0.001*
Distant 6.66 (5.31, 8.35) <0.001* 23.72 (15.20, 37.02) <0.001*
Tumor size
≤20 mm Ref. – Ref. –
>20–50 mm 1.55 (1.40, 1.72) <0.001* 2.04 (1.76, 2.38) <0.001*
>50 mm 2.32 (2.03, 2.64) <0.001* 3.16 (2.64, 3.78) <0.001*
Radiation
Yes Ref. – Ref. –
No 1.50 (1.37, 1.64) <0.001* 1.36 (1.21, 1.54) <0.001*
Surgery
Yes Ref – Ref. –
No 2.38 (2.04, 2.77) <0.001* 2.39 (1.97, 2.89) <0.001*
All values represent 10 year survival. Hazard ratios adjusted for population, age, marital status, no. of previous cancers, hormone receptor status, grade, stage, size, radiation, and sur-
gery. †Sample size (n) for both models = 7,745 observations. Overall events: 2,205. Breast cancer-specific events: 1,189.
*indicates statistical significance.
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our analysis of treatment to radiation therapy or sur-
gery. Furthermore, power was limited by the small
number of women in the BBD population. Finally,
although women in the BBD population were diagnosed
with BBD in Detroit hospitals, not all women in the
BBD population live in the Detroit metro area. There-
fore, a small number of women in the BBD population
may not have been included in the MDCSS upon devel-
oping cancer, leading to a slight underestimate of the
subsequent cancers in the cohort. Underreporting of the
cancer outcome would be unlikely to bias our results,
as we have no reason to suspect that women who do
not live in the metropolitan Detroit area develop can-
cers that differ from women who do.
In conclusion, although previous research indicates
that women with a history of BBD are at higher risk
of developing breast cancer, their cancers may differ
in clinically important ways from those of the general
population. Women with a history of BBD appear to
develop cancers that are more likely to be in situ than
invasive, more likely to be hormone receptor positive,
and less likely to cause death within 10 years of fol-
low-up. Additional study to identify higher risk benign
lesions is warranted, and could identify a subset of
women who would be more likely to derive benefit
from closer surveillance.
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